INTERVENTIONALNOT YET RECRUITINGNCT05432284
Behavioral Pharmacology of THC and Beta-Myrcene
This study will evaluate the pharmacokinetics and pharmacodynamics of vaporized b-myrcene and THC administered via inhalation.
Locally preserved from ClinicalTrials.govOpen ClinicalTrials.gov↗last source update 2026-07-31
What this record can show
Protocol only - no registry results posted
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Study at a glance
- Phase
- PHASE1
- Enrollment
- 32 (ESTIMATED)
- Start date
- 2027-07
- Sponsor
- Johns Hopkins University
- Design
- RANDOMIZED · CROSSOVER · BASIC SCIENCE
- Locations
- 1
- Results record
- Not present in registry snapshot
The proposed study will be conducted at the Johns Hopkins Behavioral Pharmacology Research Unit (BPRU). Participants will complete 9 acute drug administration periods in which they will administer THC alone, myrcene alone, THC and myrcene together, or placebo. Subjective drug effects and vital signs will be assessed following drug administration. Each participant will receive all 9 dose conditions in a randomized order using a placebo controlled within-subject crossover design. The study will help us understand the individual and interactive effects of THC and b-myrcene, two common constituents found in cannabis.
Cannabis Use
Linked local records
Related local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Conditions
No published condition report matched.
Cannabinoids and active compounds
Medicines
No exact medicine-name link was found.
Interventions
What was registered
DRUGPlacebo
Placebo (ambient air)
DRUGTHC
Pure THC vapor
CannabisDRUGBeta-Myrcene
Pure beta-myrcene vapor
Eligibility
Population and criteria
- Sex
- ALL
- Minimum age
- 18 Years
- Maximum age
- 55 Years
- Healthy volunteers
- Accepted
Inclusion criteria
- 1. Have provided written informed consent 2. Be between the ages of 18 and 55 3. Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests 4. Test negative for drugs of abuse other than cannabis, including breath alcohol at the screening visit and at clinic admission 5. Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission. 6. Have a body mass index (BMI) in the range of 18 to 36 kg/m2 7. Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg 8. Have no allergies to any of the ingredients used to prepare vapor (delta 9-THC, myrcene). 9. Demonstrate competency on cognitive performance measures at screening visit (e.g., PASAT score over 75).
Exclusion criteria
- 1. Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine 3 month prior to the Screening Visit; 2. History of or current evidence of significant medical (e.g. seizure disorder) or psychiatric illness (e.g. psychosis) judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures. 3. Use of an OTC, systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. 4. Use of a prescription medication (with the exception of birth control prescriptions) within 5 half-lives for that specific drug; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject. 5. Cannabis use that is inconsistent with protocol requirements. 6. Clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina). 7. Individuals with anemia or who have donated blood in the prior 30 days
primary outcomes
primary measures
Self-reported Drug Effect as assessed by the Drug Effect Questionnaire (DEQ)
Time frame: 6 hours
Peak rating (0-100) of Drug Effect on the DEQ, with 0 being no effect and 100 being maximum effect.
secondary outcomes
secondary measures
Self-reported "Tired/Sleepy" as assessed by the Drug Effect Questionnaire (DEQ)
Time frame: 6 hours
Peak rating (0-100) of Tired/Sleepy on the DEQ, with 0 being no effect and 100
other outcomes
other measures
Driving performance as assessed by composite drive score
Time frame: .5 hours
Driving impairment will be assessed via a composite drive score (higher scores indicate greater impairment). The composite drive score is derived by integrating various driving outcomes. There is no upper or lower limit to possible scores
Psychomotor performance as assessed by the Digit Symbol Substitution Task (DSST)
Time frame: 6 hours
Computerized version of Digit Symbol Substitution Task will be administered to assess psychomotor performance. Total correct trials in 90-seconds. Minimum score of 0 but no maximum score (higher scores indicate better performance).
Working memory performance as assessed by the Paced Auditory Serial Addition Task
Time frame: 6 hours
Computerized version of Paced Auditory Serial Addition Task will be administered to assess working memory performance. Total correct trials out of 90 recorded is primary outcome (higher scores indicate better performance).
Heart rate
Time frame: 6 hours
Heart rate (beats/minute) will be measured while sitting down using the vitals machine.
Quantitative levels of D-9-THC in blood
Time frame: 3 hours
Blood is collected through an intravenous catheter, quantitative results are reported in nanograms per milliliter (ng/ml).
Publications
Locally readable linked articles
0No exact PMID-linked public article is currently readable locally.
Snapshot provenance
- Snapshot
- b75f7747-3e6b-41cc-b2b0-8c5580542c27
- Retrieved
- 11/09/2026, 14:17:13
- SHA-256
- 11a30ed5019f0364b42e624501a44826d5c6cc9503a5d0b16f7168920230a3a4